This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.rt.com/news/538052-sputnik-light-mrna-booster/

The article has changed 2 times. There is an RSS feed of changes available.

Version 0 Version 1
Sputnik Light is universal booster shot for Covid-19 vaccines, developer says following FDA’s approval of mix & match approach Sputnik Light is universal booster shot for Covid-19 vaccines, developer says following FDA’s approval of mix & match approach
(about 1 hour later)
Russia’s one-shot Sputnik Light vaccine has been announced as safe to combine with the world’s anti-coronavirus jabs, including mRNA-method shots. It is promised to offer higher efficacy against the Delta variant in particular.Russia’s one-shot Sputnik Light vaccine has been announced as safe to combine with the world’s anti-coronavirus jabs, including mRNA-method shots. It is promised to offer higher efficacy against the Delta variant in particular.
The so-called ‘vaccine cocktail’ approach is “one of the best solutions against the pandemic,” the Russian Direct Investment Fund (RDIF), which is behind the world’s first registered Covid-19 vaccine, Sputnik V, has said. The RDIF is Russia’s sovereign wealth fund. It says the mix-and-match method not only strengthens immune response, but also increases vaccine efficacy against new mutations. The so-called ‘vaccine cocktail’ approach is “one of the best solutions against the pandemic,” the Russian Direct Investment Fund (RDIF), which is behind the world’s first registered Covid-19 vaccine, Sputnik V, has said. The RDIF is Russia’s sovereign wealth fund. It says the mix-and-match method not only strengthens immune response, but also increases vaccine efficacy against new mutations. 
Russia’s sovereign fund was the first to strike a partnership to conduct mix-and-match studies. In December 2020, just such a deal was agreed with AstraZeneca.Russia’s sovereign fund was the first to strike a partnership to conduct mix-and-match studies. In December 2020, just such a deal was agreed with AstraZeneca.
Recent research conducted in Moscow has proven that the one-shot Sputnik Light vaccine, when combined with other jabs, can boost protection against the more contagious Delta variant up to more than 83%, and help avoid hospitalization in over 94% of the cases. Recent research conducted in Moscow has proven that the one-shot Sputnik Light vaccine, when combined with other jabs, can boost protection against the more contagious Delta variant up to more than 83%, and help avoid hospitalization in over 94% of the cases. 
Initial results of a special study in Argentina have proved Sputnik Light to be an effective universal booster for vaccines like AstraZeneca, Sinopharm or Moderna. Combining various shots in one recipient will also expedite worldwide vaccination efforts, providing more flexibility to the process, the RDIF has pointed out.Initial results of a special study in Argentina have proved Sputnik Light to be an effective universal booster for vaccines like AstraZeneca, Sinopharm or Moderna. Combining various shots in one recipient will also expedite worldwide vaccination efforts, providing more flexibility to the process, the RDIF has pointed out.
The fund’s statement comes after the US Food and Drug Administration (FDA) authorized combinations of different Covid-19 doses, allowing people to receive booster shots that are different from their initial Covid jabs. In addition to Pfizer vaccines, those developed by Moderna and Johnson & Johnson may now also be used for booster doses, the top US regulator announced on Wednesday.The fund’s statement comes after the US Food and Drug Administration (FDA) authorized combinations of different Covid-19 doses, allowing people to receive booster shots that are different from their initial Covid jabs. In addition to Pfizer vaccines, those developed by Moderna and Johnson & Johnson may now also be used for booster doses, the top US regulator announced on Wednesday.
Last month, the FDA struggled to approve the Pfizer vaccine for booster shots, as studies had shown that its efficacy against the Delta variant dropped from 93% to 53% five months after vaccination. A study previously published by the Lancet showed the Pfizer vaccine's effectiveness drops over time by up to 47% six months after the second dose. Its effectiveness against hospitalization and death remains at 90%.
Like this story? Share it with a friend!Like this story? Share it with a friend!